CA-ALATION
Alation Inc. , the leader in enterprise data catalogs, today announced the results of a global study, Leverage Your Data, A Data Strategy Checklist for the Journey to the Data-Driven Enterprise , which found that while nearly every company wants to be data-driven, the lack of documentation and knowledge about data inhibits that goal. The study, sponsored by Alation and carried out by Business Application Research Center (BARC) , reveals that a key enabler to becoming a data-driven enterprise is the implementation of a successful data catalog that drives active contribution and collaboration from the business user.
According to the study, 90% of respondents indicate that data has a high priority in enterprise decision-making yet only 25% state that decisions are predominantly or purely made based on data. Several roadblocks inhibit the business user from embracing data and therefore prevent organizations from becoming data-driven. Participants report a lack of information and documentation on data, insight into who is using what data and for what purpose, and inconsistent meanings and interpretations of data as blockers. They also cite that data access is too complicated and that significant time is wasted asking the same questions about data or repeating work, further preventing business users from making data-driven decisions.
To overcome these obstacles, the report says that enterprises need to foster a data culture that empowers the business users. The data catalog drives data democratization by providing widespread access to data and encouraging a collaborative information exchange where data users – from business users to data analysts – can engage in an iterative process that ensures data quality and the proper use of data. The catalog tackles the challenges associated with data documentation by providing a business glossary that facilitates cross-departmental access to approved data definitions, ensuring that the meaning and interpretations of key figures in the organization are consistent. By removing these hurdles and empowering business users with a collaborative platform, organizations are able to unlock the true value of their data. This is why 77% of respondents currently use or are planning to use a data catalog.
“The BARC study mirrors the challenges our customers experienced prior to using Alation. Organizations need a data catalog that enables search and discovery, provides the context on how to use the data, and fosters collaboration among data users,” said Satyen Sangani, CEO and co-founder of Alation. “Alation is the foundation for building a data culture and we’re seeing more enterprises leverage our data catalog to drive that cultural shift and derive more value from their data.”
For four consecutive years, Alation has been named the top-ranked data catalog in Dresner Advisory Services’ 2020 Wisdom of Crowds® Data Catalog Market Study . Alation has also been recognized as a leader in the Forrester Wave for Machine Learning Data Catalogs , a three-time leader in Gartner’s Magic Quadrant for Metadata Management Solutions , and selected as a Gartner Peer Insights Customer’s Choice for Metadata Management Solutions .
To download a copy of Leverage Your Data, a Data Strategy Checklist for the Journey to the Data-Driven Enterprise , click here .
To learn more about the study, register for the BARC Launch Party: How do Companies Find, Understand and use Trusted Data for Analytics? which is being held twice, once at 9am CEST and once at 5pm CEST on June 25, 2020.
To learn how customers use Alation for data governance, register for our upcoming webinar with Bob Seiner, author of Non-Invasive Data Governance , and Alation customer, Riot Games on July 7, 2020.
About Alation
Alation pioneered the data catalog market, leading the evolution of data management towards driving data culture. Alation customers leverage the data catalog as a platform for data search & discovery, data governance, data stewardship, analytics, and digital transformation. With its powerful Behavioral Analysis Engine, inbuilt collaboration capabilities, and open interfaces, Alation provides a platform to support a broad range of data intelligence solutions by combining machine learning with human insight to tackle the most demanding challenges in data management. Nearly 200 organizations are driving their data cultures and improving their organizations’ decision making with Alation, including AbbVie, DraftKings, Exelon, Finnair, Genentech, GoDaddy, Marks & Spencer, MercadoLibre, Munich Re, New Balance, New Relic, Pfizer, Scandinavian Airlines, Scout24 and US Foods. Headquartered in Silicon Valley, Alation is funded by Costanoa Ventures, Data Collective Venture Capital, Icon Ventures, Sapphire Ventures, and Salesforce Ventures. For more information, visit alation.com .
About BARC
BARC (Business Application Research Center) is one of Europe’s leading analyst firms for business software, focusing on the areas of data, business intelligence (BI) and analytics, enterprise content management (ECM) and customer relationship management (CRM). The company was founded in 1999 as a spin-off of the Chair of Business Administration and Information Systems at the Julius-Maximilians-University in Würzburg. Today, BARC combines empirical and theoretical research, technical expertise and practical experience, including a constant exchange with all market participants. For more information, visit: www.barc-research.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200622005757/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
